Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5220113
Max Phase: Preclinical
Molecular Formula: C70H104IN21O22S4
Molecular Weight: 1846.90
Associated Items:
ID: ALA5220113
Max Phase: Preclinical
Molecular Formula: C70H104IN21O22S4
Molecular Weight: 1846.90
Associated Items:
Canonical SMILES: C[C@@H](O)[C@@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@H](CC(=O)N[C@@H](CCC(=O)O)C(=O)O)Cc1ccc(O)cc1)CSSC2(C)C
Standard InChI: InChI=1S/C70H104IN21O22S4/c1-33(93)54-64(110)87-44(28-53(100)101)66(112)92-23-7-11-48(92)63(109)85-41(10-6-22-79-69(76)77)58(104)88-46-31-116-115-30-45(82-51(97)29-73)62(108)91-55(65(111)90-54)70(2,3)118-117-32-47(60(106)80-36(24-34-12-15-37(94)16-13-34)27-50(96)81-42(67(113)114)17-19-52(98)99)89-57(103)39(8-4-20-72)83-59(105)43(26-35-14-18-49(95)38(71)25-35)86-56(102)40(84-61(46)107)9-5-21-78-68(74)75/h12-16,18,25,33,36,39-48,54-55,93-95H,4-11,17,19-24,26-32,72-73H2,1-3H3,(H,80,106)(H,81,96)(H,82,97)(H,83,105)(H,84,107)(H,85,109)(H,86,102)(H,87,110)(H,88,104)(H,89,103)(H,90,111)(H,91,108)(H,98,99)(H,100,101)(H,113,114)(H4,74,75,78)(H4,76,77,79)/t33-,36+,39+,40+,41+,42+,43+,44+,45-,46+,47+,48+,54+,55-/m1/s1
Standard InChI Key: KJYPAFNUDKVSQB-DATCEBALSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1846.90 | Molecular Weight (Monoisotopic): 1845.5592 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM.. (2021) Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism., 64 (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512] |
Source(1):